Home / Market News / $MRK
benzinga Corporate Catalyst Impact 75/100 ● negative

Merck, Daiichi Sankyo Voluntarily Withdraw Biologics License Application Approval In U.S. For Ifinatamab Deruxtecan To Treat Small Cell Lung Cancer After Discussions With FDA

Sep 25, 2026, 8:33 PM UTC · Primary ticker $MRK

Merck and Daiichi Sankyo have voluntarily withdrawn their Biologics License Application for ifinatamab deruxtecan (I-DXd) for extensive-stage small cell lung cancer in the U.S. This decision follows discussions with the FDA, which indicated that the submitted data, including from the IDeate-Lung01 trial, did not meet the requirements for accelerated approval. This withdrawal represents a setback for the companies' oncology pipeline in this specific indication.

Merck and Daiichi Sankyo have withdrawn their Biologics License Application for ifinatamab deruxtecan (I-DXd) for extensive-stage small cell lung cancer in the U.S. The withdrawal stems from FDA discussions indicating that the data, particularly from the IDeate-Lung01 Phase 2 trial, was insufficient for accelerated approval. This is a negative development for both companies, as it delays or potentially halts the market entry of a promising drug candidate for an unmet medical need. In the short term, this could lead to a negative sentiment for MRK and Daiichi Sankyo, impacting their stock prices. Long-term, it raises questions about the future development path for I-DXd in this indication and the companies' ability to meet regulatory standards. Traders should consider the potential for downward pressure on these stocks due to this regulatory setback.

$MRK negative Withdrawal of BLA for key drug candidate
$4568.T negative Withdrawal of BLA for key drug candidate
Source: benzinga
Join the waitlist for full signal validation →

Not financial advice. AI-generated analysis for informational purposes only.